

MARKET REPORT



PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Summary

Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue. In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable angina (UA), myocardial infarction (MI) and/or death due to myocardial ischemia. In general, these ACS events can be viewed as the culmination of coronary artery disease (CAD), the asymptomatic build-up of atherosclerotic plaque on the walls of the coronary arteries. The triggering of an ACS event stemming from UA or MI initiates the acute phase treatment setting where therapeutic interventions are utilized to reverse and prevent the physiochemical processes that lead to coronary stenosis. Whereas, the chronic phase treatment setting involves secondary preventative measures that are used to avoid recurrent ACS events from occurring.

Highlights

Key Questions Answered

- The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?
- The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases, as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?

Key Findings

- The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
- The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.

- The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
- The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.

Scope

- Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ACS therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Additional Details

Publisher : Global Data
Reference : GDHC131PIDR
Number of Pages : 416

Report Format : PDF

Publisher Information :



GlobalData»

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

- 1 Table of Contents1 Table of Contents 101.1 List of Tables 161.2 List of Figures 222 Introduction 242.1 Catalyst 242.2 Related Reports 252.3 Upcoming Related Reports 253 Disease Overview 263.1 Etiology and Pathophysiology 273.1.1 Etiology 273.1.2 Pathophysiology 313.2 Classification or Staging Systems 333.3 Symptoms 343.4 Prognosis 353.5 Quality of Life 364 Epidemiology 374.1 Disease Background 374.2 Risk Factors and Comorbidities 384.3 Global Trends 414.3.1 ACS Diagnosed Prevalence 414.3.2 STEMI and NSTEMI Trends 444.3.3 ACS Hospitalizations 454.4 Forecast Methodology 474.4.1 Sources Used 504.4.2 Forecast Assumptions and Methods 574.4.3 Sources Not Used 704.5 Epidemiological Forecast for ACS (2015-2025) 714.5.1 Diagnosed Prevalent Cases of ACS 714.5.2 Age-Specific Diagnosed Prevalent Cases of ACS 734.5.3 Sex-Specific Diagnosed Prevalent Cases of ACS 754.5.4 Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA 774.5.5 Age-Standardized Diagnosed Prevalence of ACS 794.5.6 ACS Hospitalizations 804.5.7 Sex-Specific ACS Hospitalizations 824.5.8 ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA 844.6 Discussion 864.6.1 Epidemiological Forecast Insight 864.6.2 Limitations of the Analysis 874.6.3 Strengths of the Analysis 885 Disease Management 905.1 Diagnosis and Treatment Overview 905.1.1 Diagnosis 905.1.2 Treatment Guidelines and Leading Prescribed Drugs 915.1.3 Clinical Practice 965.2 US 995.3 5EU 1025.4 Japan 1066 Competitive Assessment 1096.1 Overview 1096.2 Product Profiles - Acute Coronary Syndrome 1126.2.1 Antihypertensives 1126.2.2 Anticoagulants 1306.2.3 Fibrinolytics 1506.2.4 Antidyslipidemics 1556.2.5 Antiplatelets 1767 Unmet Need and Opportunity 2097.1 Overview 2097.2 Management of ACS in Elderly Patients 2107.2.1 Unmet Need 2107.2.2 Gap Analysis 2117.2.3 Opportunity 2127.3 Blood Thinning Agent with Reduced Bleeding 2137.3.1 Unmet Need 2137.3.2 Gap Analysis 2147.3.3 Opportunity 2147.4 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 2157.4.1 Unmet Need 2157.4.2 Gap Analysis 2167.4.3 Opportunity 2177.5 Achieving Guideline-Recommended Levels of LDL-C 2177.5.1 Unmet need 2177.5.2 Gap Analysis 2187.5.3 Opportunity 2197.6 Optimal Treatment of ACS Patients with Hyperglycemia 2207.6.1 Unmet Need 2207.6.2 Gap Analysis 2207.6.3 Opportunity 2218 Pipeline Assessment 2228.1 Overview 2228.2 Promising Drugs in Clinical Development 2248.2.1 Bococizumab 2258.2.2 Anacetrapib 2318.2.3 CSL-112 2388.2.4 CER-001 2468.2.5 LY3015014 2538.2.6 AMG-899 2578.2.7 ETC-1002 2629 Current and Future Players 2689.1 Overview 2689.2 Trends in Corporate Strategy 2739.3 Company Profiles 2759.3.1 Amgen 2759.3.2 AstraZeneca 2779.3.3 Bristol-Myers Squibb 2799.3.4 Cerenis Therapeutics 2819.3.5 CSL Limited 2829.3.6 Daiichi Sankyo 2849.3.7 Eli Lilly 2869.3.8 Esperion Therapeutics 2879.3.9 GlaxoSmithKline 2889.3.10 Janssen 2909.3.11 The Medicines Company 2919.3.12 Merck & Co. 2949.3.13 Pfizer 2969.3.14 Sanofi 29810 Market Outlook 30110.1 Global Market 30110.1.1 Forecast 30110.1.2 Drivers and Barriers - Global Issues 30810.2 United States 31310.2.1 Forecast 31310.2.2 Key Events 31810.2.3 Drivers and Barriers 31810.3 France 32010.3.1 Forecast 32010.3.2 Key Events 32510.3.3 Drivers and Barriers 32510.4 Germany 32610.4.1 Forecast 32610.4.2 Key Events 33110.4.3 Drivers and Barriers 33210.5 Italy 33310.5.1 Forecast 33310.5.2 Key Events 33810.5.3 Drivers and Barriers 33910.6 Spain 34010.6.1 Forecast 34010.6.2 Key Events 34410.6.3 Drivers and Barriers 34410.7 United Kingdom 34510.7.1 Forecast 34510.7.2 Key Events 35010.7.3 Drivers and Barriers 35010.8 Japan 35210.8.1 Forecast 35210.8.2 Key Events 35610.8.3 Drivers and Barriers 35611 Appendix 35911.1 Bibliography 35911.2 Abbreviations 38911.3 Methodology 39611.4 Forecasting Methodology 39611.4.1 Diagnosed Acute Coronary Syndrome Patients 39611.4.2 Percent Drug-Treated Patients 39711.4.3 Drugs Included in Each Therapeutic Class 39711.4.4 Launch and Patent Expiry Dates 39811.4.5 General Pricing Assumptions 39911.4.6 Individual Drug Assumptions 40011.4.7 Generic Erosion 40811.4.8 Pricing of Pipeline Agents 40911.5 Physicians and Specialists Included in this Study 41011.6 About the Authors 41311.6.1 Analyst 41311.6.2 Therapy Area Director 41311.6.3 Epidemiologist 41411.6.4 Global Director of Therapy and Epidemiology 41411.7 About GlobalData 41511.8 Disclaimer 415

List Of Tables in PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

1.1 List of Tables

Table 1: Marketed Antiplatelet Agents that Inhibit Platelet Activation 29

Table 2: Marketed Anticoagulants that Inhibit the Coagulatory Cascade 29

Table 3: Antidyslipidemic agents 31

Table 4: Classifications of ACS 33

Table 5: Universal Classification of MI 34

Table 6: Symptoms of Acute Coronary Syndrome 35

Table 7: Risk Factors and Comorbidities for ACS 40

Table 8: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants 44

Table 9: 7MM, Sources of Diagnosed Prevalence Data for MI 51

Table 10: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI 52

Table 11: 7MM, Data Sources of ACS Hospitalizations 54

Table 12: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations 56

Table 13: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 72

Table 14: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015 74

Table 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, N (Row %), 2015 76

Table 16: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ≥ 25 Years, N (Row %), 2015 78

Table 17: 7MM ACS Hospitalizations, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 81

Table 18: 7MM, Sex-Specific ACS Hospitalizations, Ages ≥ 25 Years, N (Row %), 2015 83

Table 19: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ≥ 25 Years, Both Sexes, N, 2015 85

Table 20: Most-Prescribed Drugs for ACS by Class in the Global Markets, 2015 92

Table 21: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 94

Table 22: Country Profile for ACS - US 101

Table 23: Country Profile for ACS - 5EU 104

Table 24: Country Profile for ACS - Japan 107

Table 25: Leading Treatments for ACS, 2015 110

Table 26: Commonly Used Beta Blockers	113
Table 27: Product Profile - Beta Blockers	114
Table 28: Beta Blockers SWOT Analysis, 2015	116
Table 29: Global ACS Sales Forecasts [\$m] for Beta Blockers, 2015-2025	117
Table 30: Commonly Used ACE Inhibitors	118
Table 31: Product Profile - ACE Inhibitors	119
Table 32: ACE Inhibitor SWOT Analysis, 2015	121
Table 33 Global ACS Sales Forecasts [\$m] for ACE inhibitors, 2015-2025	122
Table 34: Commonly Used ARBs	123
Table 35: Product Profile - Angiotensin Receptor Blockers (ARBs)	123
Table 36: ARB SWOT Analysis, 2015	125
Table 37: Global ACS Sales Forecasts [\$m] for ARBs, 2015-2025	126
Table 38: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs)	127
Table 39: MRA SWOT Analysis, 2016	129
Table 40: Global ACS Sales Forecasts [\$m] for MRAs, 2015-2025	130
Table 41: Product Profile - Warfarin	132
Table 42: Warfarin SWOT Analysis, 2015	134
Table 43: Global ACS Sales Forecasts [\$m] for Warfarin, 2015-2025	135
Table 44: Product Profile - Angiomax	136
Table 45: Angiomax SWOT Analysis, 2015	138
Table 46: Global ACS Sales Forecasts [\$m] for Angiomax, 2015-2025	139
Table 47: Product Profile - Fondaparinux	141
Table 48: Arixtra SWOT Analysis, 2015	143
Table 49: Global ACS Sales Forecasts (\$M) for Fondaparinux, 2015-2025	144
Table 50: Product Profile - Xarelto (rivaroxaban)	147
Table 51: Xarelto SWOT Analysis, 2015	149
Table 52: Global ACS Sales Forecast (\$M) for Xarelto, 2015-2025	150
Table 53: Commonly Used tPAs	152
Table 54: Product Profile - Tissue Plasminogen Activator (tPA)	152
Table 55: Fibrinolytics SWOT Analysis, 2015	154
Table 56: Global ACS Sales Forecast (\$M) for Fibrinolytics, 2015-2025	155

Table 57: Product Profile - Repatha (Evolocumab)	158
Table 58: Product Profile - Praluent (Alirocumab)	159
Table 59: PCSK9 inhibitors SWOT Analysis, 2015	161
Table 60: Global ACS Sales Forecasts [\$m] for Repatha, 2015-2025	162
Table 61: Global ACS Sales Forecasts [\$m] for Praluent, 2015-2025	163
Table 62: Product Profile - Atorvastatin	166
Table 63: Product Profile - Simvastatin	167
Table 64: Lipitor (Atorvastatin) SWOT Analysis, 2015	170
Table 65: Zocor (Simvastatin) SWOT Analysis, 2015	171
Table 66: Global ACS Sales Forecasts [\$m] for Generic Statins, 2015-2025	172
Table 67: Product Profile - Crestor (Rosuvastatin)	173
Table 68: Crestor (Rosuvastatin) SWOT Analysis, 2015	175
Table 69: Global ACS Sales Forecasts [\$m] for Crestor, 2015-2025	176
Table 70: Product Profile - Clopidogrel	178
Table 71: Clopidogrel SWOT Analysis, 2015	180
Table 72: Global ACS Acute Phase Sales Forecast (\$M) for Clopidogrel, 2015-2025	181
Table 73: Global ACS Chronic Phase Sales Forecasts (\$M) for Clopidogrel, 2015-2025	182
Table 74: Product Profile - Brilinta (ticagrelor)	184
Table 75: Brilinta (ticagrelor) SWOT Analysis, 2015	186
Table 76: Global Acute Phase ACS Sales Forecast (\$M) for Brilinta, 2015-2025	187
Table 77: Global ACS Chronic Phase Sales Forecast (\$M) for Brilinta, 2015-2025	188
Table 78: Product Profile - Effient (Prasugrel)	190
Table 79: Effient (Prasugrel) SWOT Analysis, 2015	192
Table 80: Global Acute Phase ACS Sales Forecast (\$M) for Effient, 2015-2025	193
Table 81: Global ACS Chronic Phase Sales Forecast (\$M) for Effient, 2015-2025	193
Table 82: Product Profile - Integrilin (Eptifibatide)	195
Table 83: Integrilin (Eptifibatide) SWOT Analysis, 2015	197
Table 84: Global ACS Sales Forecast (\$M) for Integrilin, 2015-2025	198
Table 85: Product Profile - Cangrelor	200
Table 86: Kengreal (cangrelor) SWOT Analysis, 2015	202
Table 87: Global ACS Sales Forecasts (\$M) for Kengreal, 2015-2025	203

Table 88: Product Profile - Zontivity (Vorapaxar) 205
Table 89: Vorapaxar SWOT Analysis, 2015 207
Table 90: Global ACS Sales Forecast (\$M) for Zontivity, 2015-2025 208
Table 91: Unmet Need and Opportunity in ACS 210
Table 92: Comparison of Therapeutic Classes in Development for ACS, 2015 224
Table 93: Comparison of Therapeutic Classes in Pipeline for ACS, 2016 225
Table 94: Product Profile - Bococizumab (PF-04950615) 227
Table 95: Bococizumab (PF-04950615) SWOT Analysis, 2015 230
Table 96: Global ACS Sales Forecasts [\$m] for Bococizumab, 2015-2025 231
Table 97: Product Profile - Anacetrapib 234
Table 98: Anacetrapib SWOT Analysis, 2015 237
Table 99: Global ACS Sales Forecasts [\$m] for Anacetrapib, 2015-2025 238
Table 100: Product Profile - CSL-112 241
Table 101: CSL-112 SWOT Analysis, 2015 244
Table 102: Global ACS Sales Forecasts [\$m] for CSL-112, 2015-2025 245
Table 103: Product Profile - CER-001 248
Table 104: CER-001 SWOT Analysis, 2015 251
Table 105: Global ACS Sales Forecasts [\$m] for CER-001, 2015-2025 252
Table 106: Product Profile - LY3015014 254
Table 107: LY3015014 SWOT Analysis, 2015 256
Table 108 Global ACS Sales Forecasts [\$m] for LY3015014 , 2015-2025 257
Table 109: Product Profile - AMG-899 259
Table 110: AMG-899 SWOT Analysis, 2015 261
Table 111: Global ACS Sales Forecasts [\$m] for AMG-899, 2015-2025 262
Table 112: Product Profile - ETC-1002 264
Table 113: ETC-1002 SWOT Analysis, 2016 266
Table 114: Global ACS Sales Forecasts [\$m] for ETC-1002, 2015-2025 267
Table 115: Key Companies in the ACS Market, 2016 272
Table 116: Amgen's ACS Portfolio Assessment, 2016 276
Table 117: AstraZeneca's ACS Portfolio Assessment, 2015 279
Table 118: BMS's ACS Portfolio Assessment, 2015 281

Table 119: Cerenis' ACS Portfolio Assessment, 2015 282

Table 120: CSL Limited's ACS Portfolio Assessment, 2015 283

Table 121: Daiichi Sankyo's ACS Portfolio Assessment, 2015 285

Table 122: Eli Lilly's ACS Portfolio Assessment, 2015 287

Table 123: Esperion's ACS Portfolio Assessment, 2016 288

Table 124: GlaxoSmithKline's Acute Coronary Syndrome Portfolio Assessment, 2015 290

Table 125: Janssen's ACS Portfolio Assessment, 2015 291

Table 126: The Medicines Company's Acute Coronary Syndrome Portfolio Assessment, 2015 294

Table 127: Merck's ACS Portfolio Assessment, 2015 296

Table 128: Pfizer's ACS Portfolio Assessment, 2015 298

Table 129: Sanofi's ACS Portfolio Assessment, 2015 300

Table 130: Global Sales Forecasts [\$m] for Acute Coronary Syndrome, 2015-2025 304

Table 131: ACS Global market - Drivers and Barriers, 2015-2025 308

Table 132: Sales Forecasts [\$m] for Acute Coronary Syndrome in the US, 2015-2025 315

Table 133: Key Events Impacting Sales for ACS in the US, 2015-2025 318

Table 134: US ACS Market - Drivers and Barriers, 2015-2025 318

Table 135: Sales Forecasts [\$m] for Acute Coronary Syndrome in France, 2015-2025 322

Table 136: Key Events Impacting Sales for ACS in France, 2015-2025 325

Table 137: France ACS market - Drivers and Barriers, 2015-2025 325

Table 138: Sales Forecasts [\$m] for Acute Coronary Syndrome in Germany, 2015-2025 328

Table 139: Key Events Impacting Sales for ACS in Germany, 2015-2025 331

Table 140: Germany ACS market - Drivers and Barriers, 2015-2025 332

Table 141: Sales Forecasts [\$m] for Acute Coronary Syndrome in Italy, 2015-2025 335

Table 142: Key Events Impacting Sales for ACS in Italy, 2015-2025 338

Table 143: Italy ACS market - Drivers and Barriers, 2015-2025 339

Table 144: Sales Forecasts [\$m] for Acute Coronary Syndrome in Spain, 2015-2025 341

Table 145: Key Events Impacting Sales for ACS in Spain, 2015-2025 344

Table 146: Spain ACS Market - Drivers and Barriers, 2015-2025 344

Table 147: Sales Forecasts [\$m] for Acute Coronary Syndrome in the UK, 2015-2025 347

Table 148: Key Events Impacting Sales for ACS in the UK, 2015-2025 350

Table 149: UK ACS market - Drivers and Barriers, 2015-2025 350

Table 150: Sales Forecasts [\$m] for Acute Coronary Syndrome in Japan, 2015-2025 353

Table 151: Key Events Impacting Sales for ACS in Japan, 2015-2025 356

Table 152: Japan ACS Market - Drivers and Barriers, 2015-2025 356

Table 153: Key ACS Launch Dates 398

Table 154: Key Patent Expiries 398

Table 155: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 412

List Of Figures, Charts and Diagrams in PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 27

Figure 2: Progression of CAD, Atherosclerotic Plaque Rupture, Thrombosis, and ACS 28

Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 30

Figure 4: Electrocardiography in the Diagnosis of ACS 32

Figure 5: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008 42

Figure 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%) 44

Figure 7: Case Segmentation Map 50

Figure 8: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 73

Figure 9; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015 75

Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, N, 2015 77

Figure 11: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ≥ 25 Years, N, 2015 79

Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ≥ 25 Years, 2015 80

Figure 13: 7MM ACS Hospitalizations, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 82

Figure 14: 7MM, Sex-Specific ACS, Ages ≥ 25 Years, N, 2015 84

Figure 15: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ≥ 25 Years, Both Sexes, N, 2015 86

Figure 16: Company Portfolio Gap Analysis in ACS, 2015-2025 271

Figure 17: Global Sales for ACS by Region, 2015-2025 306

Figure 18: Global Sales for ACS by Class, 2015-2025 307

Figure 19 Global Sales for PCSK9 inhibitors for ACS, 2015-2025 308

Figure 20: Sales for ACS in the US by Drug Class, 2015-2025 317

Figure 21: Sales for ACS in France by Drug Class, 2015-2025 324

Figure 22: Sales for ACS in Germany by Drug Class, 2015-2025 330

Figure 23: Sales for ACS in Italy by Drug Class, 2015-2025 337

Figure 24: Sales for ACS in Spain by Drug Class, 2015-2025 343

Figure 25: Sales for ACS in the UK by Drug Class, 2015-2025 349

Figure 26: Sales for ACS in Japan by Drug Class, 2015-2025 355

<https://www.bioportfolio.co.uk/product/27679>
reportstore@bioportfolio.com to order

How to Buy...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27679>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$10995** | Single User Price
- \$21990** | Site License Price
- \$32985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.